ArticleBMC oral health2025
Effect of long-acting β2-agonist and corticosteroid combination treatment on parotid glands of rats (histological and immunohistochemical study).
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBronchial asthma is a common chronic condition frequently managed with corticosteroids, β2 receptor agonists, or their combination. While these therapies effectively control respiratory symptoms, emerging evidence suggests they may adversely affect oral and salivary gland health. However, most existing studies focus on inhalation-related tooth erosion or xerostomia, with limited histological evidence on glandular changes. This study uniquely investigates the direct impact of combination therapy of salmeterol and fluticasone propionate on the parotid glands using histological and immunohistochemical analyses.
objectiveto evaluate the possible effect of long-acting β2-agonist (Salmeterol) and corticosteroid (Fluticasone propionate) combination treatment on parotid glands and assess the histological and immunohistochemical changes. MATERIALS AND
methods36 male albino rats were allocated into control and experimental groups. The experimental group received daily intraperitoneal injections of a combination of salmeterol and fluticasone propionate powder at a dosage of 0.55 mg/kg/day, while the control group was administered an equal volume of saline. Nine rats from each group were sacrificed at 14 and 25 days of treatment. The parotid glands were dissected at each time point and subjected to histological examination using H&E and immunohistochemical staining for α-SMA.
resultsHistological examination of group II after 14 days, serous acini appeared spherical with hyperchromatic nuclei, while ducts showed epithelial thinning and stagnant secretion. By 25 days, acini became irregular with cytoplasmic vacuolations, increased spacing, and inflammatory infiltration. Engorged blood vessels were observed. Immunohistochemical results using anti-α-SMA staining proved a significant decrease in myoepithelial activity compared to the control group.
conclusionsProlonged combination treatment leads to quantitative and qualitative changes in parotid salivary glands, potentially impacting oral and dental health. Therefore, greater attention should be given to the oral health of individuals using this medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.